For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
The immune system is a complex system of structures and processes that have evolved to protect us from disease. At Abcam, we are focused on identifying and prioritizing the most relevant targets in our pipeline for best-in-class reagents across infectious diseases (including COVID-19, as well as a whole spectrum of pathogens, from well-studied to emerging), autoimmunity, immunodeficiency, and allergy.
Flow cytometry is the core method for many immunologists. We are continuously expanding our collection of flow cytometry validated antibodies to offer multiple dye choices, as well as a wide range of both intracellular and extracellular targets.
View our flow cytometry tools
Abcam offers a broad range of tools to support scientists working on SARS-CoV-2, including antibodies, ELISA kits, proteins, and cell lines used to detect the virus itself and related immune response proteins cytokines and chemokines.
In addition to products already on our catalog, we have a broad selection of recombinant reagents currently moving through our pipeline, which detect all proteins present in the COVID-19 virus. These include the widely discussed spike and nucleocapsid proteins and other targets known to help the virus spread and escape the surveyance of the human immune system.
The COVID-19 pandemic has raised awareness of the importance and necessity of conducting research on infectious diseases to be better prepared for any future pandemic.
We aim to support researchers with their most acute needs today, as well as help them tackle the big questions of tomorrow. Our portfolio covers a broad range of well-studied pathogens including HIV and Hepatitis, respiratory pathogens such as Influenza, Respiratory Syncytial Virus, and Pneumonia, as well as emerging pathogens with the greatest public health risk due to their pandemic potential (according to WHO) such as Zika, Ebola, and Nipah.
With a continuously increasing incidence of autoimmune disorders worldwide, research into translational immunology is as important as ever. Our focus areas within autoimmune diseases are aligned with the major players in the pharmaceutical industry and cover rheumatology (Rheumatoid arthritis and Lupus), gastroenterology (Inflammatory Bowel disease, including Ulcerative Colitis and Crohn’s disease), and dermatology (Psoriasis).
We collaborate with researchers around the world to develop our leading reagents pipeline.
Contact us at email@example.com